Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $15.17

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $15.17.

A number of equities research analysts have recently issued reports on ELAN shares. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were bought at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares of the company’s stock, valued at $1,136,881.80. This represents a 9.86 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.57% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in ELAN. FMR LLC increased its holdings in Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company’s stock valued at $487,213,000 after purchasing an additional 37,022,891 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Elanco Animal Health by 76.6% during the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after buying an additional 4,361,799 shares during the period. Norges Bank acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at $47,424,000. Brandes Investment Partners LP raised its holdings in shares of Elanco Animal Health by 66.9% in the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock valued at $69,405,000 after buying an additional 2,296,691 shares during the period. Finally, Freestone Grove Partners LP acquired a new position in Elanco Animal Health during the 4th quarter worth about $20,396,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 3.8 %

ELAN opened at $10.40 on Wednesday. The company has a market cap of $5.14 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health has a twelve month low of $10.03 and a twelve month high of $18.80. The company has a 50-day moving average price of $11.23 and a 200 day moving average price of $12.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.08 EPS. Sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.